Biologics with a total of $67 bln in global sales will lose patent protection by 2020

Twelve biologics with total global sales of $67 bln will meet generics competition by 2020.

Read more

Common drug registration rules for countries in the Customs Union are anticipated by 2016

Currently drugs are the only commodity that cannot move freely between Russia, Belarus and Kazakhstan.

Read more

Pfizer is interested in acquiring Actavis in order to avoid high US taxes

Similar proposition by Pfizer was rejected for the fourth time by AstraZeneca earlier this year.

Read more

Analysts are anticipating market growth in 2014

RNC Pharma is forecasting the retail sector to grow by 10-12%, hospital sector – 12-15%.

Read more

USA budget will save 250 bln USD by 2014 by switching to biosimilars

Biosimilars have been available in Europe since 2006. Novartis is currently waiting on FDA decision on its first in the US biosimilar of Neupogen.

Read more

Russian companies developed and submitted to the Minister of Health Veronika Skvortsova a proposal of rules governing studies of biosimilars

A number of Russian companies including BIOCAD, Generium, GEROPHARM, ChemRar, R-pharm, Sotex, Pharmstandard and others developed Rules for conducting studies of biosimilars.

Read more

Merck Serono will market products manufactured by Lupin

German-based Merck Serono and Indian company Lupin recently became partners. Lupin will manufacturer products that will be marketed by Merck Serono in developing markets.

Read more

Russian pharmaceutical market 2013

Since recently experts haven’t had single opinion on the volume and dynamics of the Russian pharmaceutical market as a whole as well as its main sectors. Aggregate market value in 2013 is evaluated at 750–80 bn Rbls, consisting of three major segments: retail (out-of-pocket), hospital and reimbursable drug coverage.

Retail…

Read more